Figure 1 (Figure1)
This text presents survival distributions showing the proportion of subjects without coronary heart disease death or nonfatal myocardial infarction over five years since randomization. The data indicates a statistically significant difference in event-free survival between the placebo group and the group taking pravastatin, with a Logrank P-value of 0.0001.*